RxDoctor Payments DataLook up a doctor →

Mark Goldstein, MD

Hematology & Oncology · Germantown, MDNPI 1649216342

Payments from drug & device makers

$663,425in general payments, 2019–2025

Across 639 payments — averaging $1038.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$148K
  • Merck$98K
  • Astrazeneca UK Limited$89K
  • Aadi Bioscience, Inc.$87K
  • Amgen$64K
  • Pfizer$56K
  • plus $120K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)44$148,439
Merck40$98,393
Astrazeneca UK Limited2$88,983
Aadi Bioscience, Inc.8$87,092
Amgen20$64,221
Pfizer33$56,039
Janssen Research & Development, LLC7$50,487
Genentech, Inc.14$30,495
GSK15$21,596
Tempus AI, Inc8$6,304
Novartis58$1,423
Johnson & Johnson(2 entities)51$1,213
Bristol Myers Squibb17$462
Daiichi Sankyo Inc.17$437
Genentech USA, Inc.15$417
Astellas Pharma US Inc17$417
Gilead(2 entities)11$371
Takeda Pharmaceuticals U.S.A., Inc.12$363
Pharmaessentia USA Corporation12$357
AbbVie14$352
E.r. Squibb & Sons, L.L.C.12$306
Sanofi9$283
Seagen Inc.12$264
Regeneron Healthcare Solutions, Inc.9$252
Eisai Inc.11$241
Incyte Corporation11$233
Pharmacyclics LLC, An Abbvie Company9$199
Puma Biotechnology, Inc.10$188
AVEO Pharmaceuticals, Inc.7$181
Rigel Pharmaceuticals, Inc.8$179
Beone Medicines USA, Inc.5$176
Beigene USA, Inc.5$164
Exelixis Inc.6$159
TG Therapeutics, Inc.2$158
Array Biopharma Inc6$146
Taiho Oncology, Inc.5$131
EMD Serono, Inc.5$126
Myovant Sciences Inc.3$104
Mirati Therapeutics, Inc.3$94
Genmab U.S., Inc.3$92
Bayer4$92
Acrotech Biopharma Inc.5$91
Lilly USA, LLC4$77
Adaptive Biotechnologies Corporation4$76
Agios Pharmaceuticals, Inc.1$75
EUSA Pharma (US) LLC3$72
G1 Therapeutics, Inc.3$71
Sobi, Inc3$68
Ipsen Biopharmaceuticals, Inc3$65
Tersera Therapeutics LLC3$61
Syndax Pharmaceuticals, Inc.2$61
Deciphera Pharmaceuticals Inc.3$60
GE HealthCare1$60
Progenics Pharmaceuticals, Inc.1$59
Coherus Oncology, Inc.3$58
Blueprint Medicines Corporation2$53
Stemline Therapeutics Inc.2$49
Azurity Pharmaceuticals, Inc.2$47
Tactile Systems Technology Inc1$47
Portola Pharmaceuticals, LLC3$45

How this compares

$663,425 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$2,033,070
Medicare patients
605
Services billed
82,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Germantown

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →